Wolff SMBiological effects of bacterial endotoxins in man. J Infect Dis1973; 128 (Suppl): 733—758.
4.
Wallach D., Holtmann H., Engelmann H., Nophar Y.Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J Immunol1988; 140: 2994—2999.
5.
Dinarello CABiological basis for interleukin-1 in disease . Blood1996; 87: 20952147.
6.
Elliott MJ, Maini RN, Feldmann M., Kalden JR, Antoni C., Smolen JS et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis . Lancet1994; 344: 1105—1110.
7.
Lebsack ME, Paul CC, Martindale JJ, Catalano MAA dose- and regimen-ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis [abstract]. Arthritis Rheum1993; 36: S39.
8.
Bresnihan B. , Lookabaugh J., Witt K., Musikic P.Treatment with recombinant human interleukin-1 receptor antagonist in rheumatoid arthritis: results of a randomized, double-blind, placebo-controlled multicenter trial [abstract]. Arthritis Rheum1996; 39: S73.
9.
Watt I., Cobby M.Recombinant human interleukin-1 receptor antagonist reduces the rate of joint erosion in rheumatoid arthritis [abstract]. Arthritis Rheum1996; 39: S123.
10.
van Dullemen HM, van Deventer Sjh, Hommes DW, Bijl HA, Jansen J., Tytgat GN et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology1995; 109: 129—135.
11.
Antin JH, Weinstein HJ, Guinan EC, McCarthy P., Bierer BE, Gilliland DG et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood1994; 84: 1342—1348
12.
Zeni F., Freeman B., Natanson C.Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment . Crit Care Med1997; 25: 1095—1100.